Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rubitecan in metastatic urothelial tract tumors
NCT00006026Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2000
- Primary completion
- Oct 2001
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of rubitecan in urothelial carcinoma (UC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response. Started May 2000; status: completed.
02
Drugs
rubitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00006026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006026.